MedTrace Logo

Anxiety, Inflammation, Stress, and Cannabinoids

NCT03491384 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 361

Last updated 2025-08-27

Study results available
· View outcomes & findings →

Summary

This study investigates whether the anxiolytic effects and anti-inflammatory properties of cannabis vary as a function of the ratio of CBD to THC, with the goal that these effects may shed light on the mixed data linking cannabis use and anxiety. Individuals with mild to moderate anxiety who elect to use cannabis (smoked flower or edible) will complete four weeks of observation. Participants complete cognitive tasks, a substance use history, health questionnaires concerning sleep and physical activity, and a blood draw at four different time points (Baseline, after 2 weeks of cannabis use, and immediately before and after self-administration after 4 weeks of use) with the use of a mobile pharmacology laboratory, which goes to a convenient location for each participant to self-administer their cannabis. Participants are then followed for five months to self-report on cannabis use, anxiety, subjective cognitive functioning, sleep quality, and other mental health symptoms.

Conditions

  • Anxiety
  • Anxiety Disorders
  • Anxiety Generalized
  • Anxiety Chronic
  • Inflammation
  • Inflammatory Response

Interventions

DRUG

Cannabis (smoked flower, ingested edible)

Self-Directed Use (ad-libitum)

Sponsors & Collaborators

  • University of Colorado, Denver

    collaborator OTHER

  • University of Colorado, Boulder

    lead OTHER

Principal Investigators

  • Cinnamon Bidwell, PhD · University of Colorado, Boulder

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2022-12-30
Completion
2023-05-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03491384 on ClinicalTrials.gov